No data available.
Please log in to see this content.
You have no subscription access to this content.
The full text of this article is not currently available.
クリルオイル“SUPERBA BoostTM”が日本人成人男女の肌バリア機能に与える影響―ランダム化プラセボ対照二重盲検並行群間比較試験―
Rent:
Rent this article for
JPY
Abstract
Objective This study investigated the effects of consuming food product containing Krill Oil SUPERBA BoostTM for 12 weeks on skin function in healthy Japanese adults with normal to slightly dry skin(Transepidermal water loss; TEWL 15–30 g/m2/h). Methods The test product contained 70 mg docosahexaenoic acid and 150 mg eicosapentaenoic acid derived from Krill oil per capsule while the placebo contained vegetable oil. Participants were instructed to take 2 capsules of either test product or placebo per day. They were randomly assigned to either Krill oil or placebo group using a computer–generated randomization list, with stratified block random assignment using age(<40 or ≥40)as the adjustment factor. Evaluation items included TEWL(the primary outcome), elasticity and moisture content of skin on the inner right forearm, Omega–3 index, and facial microscopic observation. The evaluation time points were pre–intervention(0 w), 6 weeks and 12 weeks post–intervention(6 w and 12 w).Results Two participants dropped out after allocation, and Intention To Treat(ITT)was used as the final dataset(26 in the Krill oil group and 28 in the placebo group). The change of TEWL from 0 w to 12 w, the primary outcome of this study, was significantly lower in the Krill oil group compared to the placebo group. In addition, the lower eyelid pore size at 12 w was significantly improved in the Krill oil group, compared to the placebo group. Furthermore, the Omega–3 Index was significantly higher in the Krill oil group, compared to the placebo group at 6 w and 12 w, as well as all changes from 0 w. Conclusions Consumption of food product containing Krill Oil SUPERBA BoostTM for 12 weeks significantly decreased TEWL, suggesting its ability to maintain skin function. Trial registration UMIN000045734 Funding AKER BIOMARINE ANTARCTIC AS(Jpn Pharmacol Ther 2023;51:1013‒29)
Full text loading...
/content/article/0386-3603/51070/1013